Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286

An interactive web-based dashboard to track COVID-19 in real time

Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K. W., Bleicker, T., Brünink, S., Schneider, J. A., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,266

Factors associated with COVID-19-related death using OpenSAFELY

Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020) · Nature · doi:10.1038/s41586-020-2521-4 · Cited by 6,674

Virological assessment of hospitalized patients with COVID-2019

Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114583 · Cited by 1,703

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Gruell, H., Vanshylla, K., Tober-Lau, P., Hillus, D., Schommers, P., Lehmann, C., Kurth, F., Sander, L. E., & Klein, F. (2022) · Nature Medicine · doi:10.1038/s41591-021-01676-0 · Cited by 410

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

Hillus, D., Schwarz, T., Tober‐Lau, P., Vanshylla, K., Hastor, H., Thibeault, C., Jentzsch, S., Helbig, E. T., Lippert, L. J., Tscheak, P., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00357-x · Cited by 336

Immunity to SARS‐CoV‐2 induced by infection or vaccination

Dopico, X. C., Ols, S., Loré, K., & Hedestam, G. B. K. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13372 · Cited by 172

Antibody-mediated neutralization of SARS-CoV-2

Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 150

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Wei, J., Matthews, P. C., Stoesser, N. E., Maddox, T., Lorenzi, L., Studley, R., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26479-2 · Cited by 136

Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner

Keeton, R., Richardson, S. I., Moyo-Gwete, T., Hermanus, T., Tincho, M. B., Benede, N., Manamela, N. P., Baguma, R., Makhado, Z., Ngomti, A., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.10.003 · Cited by 109

Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection

Yang, Y., Yang, M., Peng, Y., Liang, Y., Wei, J., Xing, L., Guo, L., Li, X., Li, J., Wang, J., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01051-2 · Cited by 111

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern

Dupont, L., Snell, L. B., Graham, C., Seow, J., Merrick, B., Lechmere, T., Maguire, T. J. A., Hallett, S. R., Pickering, S., Charalampous, T., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00974-0 · Cited by 102

The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?

Boyton, R. J., & Altmann, D. M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00631-x · Cited by 101

Point-of-care diagnostics: recent developments in a pandemic age

Harpaldas, H., Arumugam, S., Rodriguez, C. C., Kumar, B. A., Shi, V. Y., & Sia, S. K. (2021) · Lab on a Chip · doi:10.1039/d1lc00627d · Cited by 82

SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns

Gruell, H., Vanshylla, K., Korenkov, M., Tober‐Lau, P., Zehner, M., Münn, F., Janicki, H., Augustin, M., Schommers, P., Sander, L. E., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.07.002 · Cited by 77

Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers

Tober-Lau, P., Schwarz, T., Vanshylla, K., Hillus, D., Gruell, H., EICOV/COVIM Study Group, Suttorp, N., Landgraf, I., Kappert, K., Seybold, J., et al. (2021) · doi:10.1101/2021.08.26.21262468 · Cited by 69

Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?

van den Hoogen, L. L., Smits, G. P., van Hagen, C. C. E., Wong, D., Vos, E. R. A., van Boven, M., de Melker, H. E., van Vliet, J., Kuijer, M., Woudstra, L., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.009 · Cited by 58

Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers

Vanshylla, K., Fan, C., Wunsch, M., Poopalasingam, N., Meijers, M., Kreer, C., Kleipass, F., Ruchnewitz, D., Ercanoglu, M. S., Gruell, H., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.010 · Cited by 58

Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses

Feldman, J. E., Bals, J., Altomare, C. G., Denis, K. S., Lam, E. C., Hauser, B. M., Ronsard, L., Sangesland, M., Moreno, T. B., Okonkwo, V., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl5842 · Cited by 60

Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Halwe, S., Kupke, A., Vanshylla, K., Liberta, F., Gruell, H., Zehner, M., Rohde, C., Krähling, V., Serra, M. G., Kreer, C., et al. (2021) · Viruses · doi:10.3390/v13081498 · Cited by 53

The way of SARS-CoV-2 vaccine development: success and challenges

Dong, Y., Dai, T., Wang, B., Zhang, L., Zeng, L., Huang, J., Yan, H., Zhang, L., & Zhou, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00796-w · Cited by 53

Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection

Wang, H., Yuan, Y. L., Xiao, M., Chen, L., Zhao, Y., Zhang, H., Long, P., Zhou, Y., Xu, X., Lei, Y., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00708-6 · Cited by 53

Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters

Burckhardt, R. M., Dennehy, J. J., Poon, L. L. M., Saif, L. J., & Enquist, L. W. (2021) · Journal of Virology · doi:10.1128/jvi.01973-21 · Cited by 52

mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects

Fabricius, D., Ludwig, C., Scholz, J. A. M., Rode, I., Tsamadou, C., Jacobsen, E., Winkelmann, M., Grempels, A., Lotfi, R., Janda, A., et al. (2021) · Vaccines · doi:10.3390/vaccines9080918 · Cited by 42

Longitudinal Systemic and Mucosal Immune Responses to SARS-CoV-2 Infection

Wright, P. F., Prevost-Reilly, A., Natarajan, H., Brickley, E. B., Connor, R. I., Wieland‐Alter, W., Miele, A. S., Weiner, J. A., Nerenz, R. D., & Ackerman, M. E. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac065 · Cited by 44

Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion

Eser, T. M., Baranov, O., Huth, M., Ahmed, M. I. M., Deák, F., Held, K., Lin, L., Pekayvaz, K., Leunig, A., Nicolai, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38020-8 · Cited by 41

Seropositivity in blood donors and pregnant women during the first year of SARS‐CoV‐2 transmission in Stockholm, Sweden

Dopico, X. C., Muschiol, S., Christian, M., Hanke, L., Sheward, D. J., Grinberg, N. F., Rorbach, J., Bogdanović, G., McInerney, G. M., Allander, T., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13304 · Cited by 36

mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants

Yu, Y., Esposito, D., Kang, Z., Lü, J., Remaley, A. T., Giorgi, V. D., Chen, L. N., West, K. A., & Cao, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-06629-2 · Cited by 40

Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study

Singh, A. K., Phatak, S., Singh, R., Bhattacharjee, K., Singh, N. K., Gupta, A., & Sharma, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102424 · Cited by 36

Enhanced SARS-CoV-2 humoral immunity following breakthrough infection builds upon the preexisting memory B cell pool

Weber, T., Dähling, S., Rose, S., Affeldt, P., Vanshylla, K., Ullrich, L., Gieselmann, L., Teipel, F., Gruell, H., Cristanziano, V. D., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adk5845 · Cited by 36

Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020

Wagner, R., Peterhoff, D., Beileke, S., Günther, F., Berr, M., Einhauser, S., Schütz, A., Niller, H. H., Steininger, P. A., Knöll, A., et al. (2021) · Viruses · doi:10.3390/v13061118 · Cited by 41

Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein

de Castro, J. T., de Azevedo, P. O., Fumagalli, M. J., Hojo-Souza, N. S., Salazar, N., Almeida, G. G., Oliveira, L. I., Faustino, L., Antonelli, L. R. D. V., Marçal, T. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32547-y · Cited by 37

Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel

Glück, V., Grobecker, S., Köstler, J., Tydykov, L., Bertok, M., Weidlich, T., Gottwald, C., Salzberger, B., Wagner, R., Zeman, F., et al. (2021) · Infection · doi:10.1007/s15010-021-01703-9 · Cited by 35

B lymphocytes in COVID-19: a tale of harmony and discordance

Mansourabadi, A. H., Aghamajidi, A., Dorfaki, M., Keshavarz, F., Shafeghat, Z., Moazzeni, A., Arab, F. L., Rajabian, A., Roozbehani, M., Falak, R., et al. (2023) · Archives of Virology · doi:10.1007/s00705-023-05773-y · Cited by 35

Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants

Korenkov, M., Zehner, M., Cohen‐Dvashi, H., Borenstein-Katz, A., Kottege, L., Janicki, H., Vanshylla, K., Weber, T., Gruell, H., Koch, M., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.004 · Cited by 36

Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort

Menges, D., Zens, K. D., Ballouz, T., Caduff, N., Llanas-Cornejo, D., Aschmann, H. E., Domenghino, A., Pellaton, C., Perreau, M., Fenwick, C. W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32573-w · Cited by 32

SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod

Meyer‐Arndt, L., Braun, J., Fauchère, F., Vanshylla, K., Loyal, L., Henze, L., Kruse, B., Dingeldey, M., Jürchott, K., Mangold, M., et al. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329395 · Cited by 33

SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response

Takamatsu, Y., Omata, K., Shimizu, Y., Kinoshita, N., Terada, M., Suzuki, T., Morioka, S., Uemura, Y., Ohmagari, N., Maeda, K., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02716-22 · Cited by 35

Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months

Robertson, L. J., Moore, J. S., Blighe, K., Ng, K. Y., Quinn, N., Jennings, F., Warnock, G., Sharpe, P. C., Clarke, M., Maguire, K., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-048142 · Cited by 29

Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity

zu Natrup, C. M., Tscherne, A., Dahlke, C., Ciurkiewicz, M., Shin, D., Fathi, A., Rohde, C., Kalodimou, G., Halwe, S., Limpinsel, L., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159895 · Cited by 32

Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection

Pradenas, E., Trinité, B., Urrea, V., Marfil, S., Tarrés-Freixas, F., Ortiz, R., Rovirosa, C., Rodon, J., Vergara‐Alert, J., Segalés, J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100523 · Cited by 29

Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults

Rennert, L., Ma, Z., McMahan, C. S., & Dean, D. (2022) · Nature Communications · doi:10.1038/s41467-022-31469-z · Cited by 31

Structural Immunology of SARS ‐ CoV ‐2

Yuan, M., & Wilson, I. A. (2024) · Immunological Reviews · doi:10.1111/imr.13431 · Cited by 29

Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG

Eberhardt, K. A., Dewald, F., Heger, E., Gieselmann, L., Vanshylla, K., Wirtz, M., Kleipass, F., Johannis, W., Schommers, P., Gruell, H., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9040733 · Cited by 26

Evaluation of Clove Phytochemicals as Potential Antiviral Drug Candidates Targeting SARS-CoV-2 Main Protease: Computational Docking, Molecular Dynamics Simulation, and Pharmacokinetic Profiling

Manivannan, A. C., Malaisamy, A., Eswaran, M., Meyyazhagan, A., Arumugam, V. A., Rengasamy, K. R. R., Balasubramanian, B., & Liu, W. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.918101 · Cited by 27

Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection

Perez‐Saez, J., Zaballa, M.-E., Lamour, J., Yerly, S., Dubos, R., Courvoisier, D. S., Villers, J., Balavoine, J.-F., Pittet, D., Kherad, O., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38744-7 · Cited by 22

Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination

Underwood, A. P., Sølund, C. S., Fernandez-Antunez, C., Villadsen, S. L., Mikkelsen, L. S., Fahnøe, U., Bollerup, S., Winckelmann, A. A., Schneider, U. V., Binderup, A., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104475 · Cited by 21

Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals

Hirotsu, Y., Amemiya, K., Sugiura, H., Shinohara, M., Takatori, M., Mochizuki, H., & Omata, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.722766 · Cited by 22

A comprehensive assessment of long-term SARS-CoV-2–specific adaptive immune memory in convalescent COVID-19 Solid Organ Transplant recipients

Favà, A., Donadeu, L., Jouvé, T., González‐Costello, J., Lladó, L., Santana, C., Toapanta, N., Comabella, M., Pernin, V., Facundo, C., et al. (2022) · Kidney International · doi:10.1016/j.kint.2021.12.029 · Cited by 21

Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors

Barnes, T. W., Schulte-Pelkum, J., Steller, L., Filchtinski, D., Jenness, R., Williams, M. R., Kober, C., Manni, S., Hauser, T., Hahn, A., et al. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108871 · Cited by 21

Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset

Law, J. C., Girard, M., Chao, G. Y. C., Ward, L. A., Isho, B., Rathod, B., Colwill, K., Li, Z., Rini, J. M., Yue, F. Y., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100727 · Cited by 23

Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection

Alexandre, M., Marlin, R., Prague, M., Coléon, S., Kahlaoui, N., Cardinaud, S., Naninck, T., Delache, B., Surénaud, M., Galhaut, M., et al. (2022) · eLife · doi:10.7554/elife.75427 · Cited by 26

Pre-existing neutralizing antibodies against cattle-transmitted influenza A virus H5N1 are detectable in unexposed individuals

Daniel, K., Ullrich, L., Ruchnewitz, D., Meijers, M., Halwe, N. J., Wild, U., Eberhardt, J., Schön, J., Stumpf, R., Schlotz, M., et al. (2026) · Immunity · doi:10.1016/j.immuni.2025.12.013 · Cited by 17

Factors influencing the immune response over 15 months after SARS‐CoV‐2 infection: A longitudinal population‐wide study in the Faroe Islands

Petersen, M. S., Pérez‐Alós, L., Armenteros, J. J. A., Hansen, C. B., Fjallsbak, J. P., Larsen, S., Hansen, J. L., Jarlhelt, I., Kristiansen, M. F., Streym, F. V., et al. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13560 · Cited by 18

Dynamics and durability of HIV-1 neutralization are determined by viral replication

Schommers, P., Kim, D. S., Schlotz, M., Kreer, C., Eggeling, R., Hake, A., Stecher, M., Park, J., Radford, C. E., Dingens, A. S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02582-3 · Cited by 17

Cohort profile:Stop the Spread Ottawa (SSO)—a community-based prospective cohort study on antibody responses, antibody neutralisation efficiency and cellular immunity to SARS-CoV-2 infection and vaccination

Collins, E., Galipeau, Y., Arnold, C. R., Bosveld, C. J., Heiskanen, A., Keeshan, A., Nakka, K. K., Shir-Mohammadi, K., Bissonnette, F. S.-D., Tamblyn, L., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062187 · Cited by 16

Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study

Owusu‐Boaitey, N., Russell, T., Meyerowitz‐Katz, G., Levin, A., & Herrera, D. (2023) · Eurosurveillance · doi:10.2807/1560-7917.es.2023.28.21.2200809 · Cited by 13

Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine primingPreprint

Zhang, Z., Wu, S., Liu, Y., Li, K., Fan, P., Song, X., Wang, Y., Zhao, Z., Zhang, X., Shang, J., et al. (2022) · medRxiv · doi:10.1101/2022.03.08.22271816 · Cited by 16

Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose

Mangia, A., Serra, N., Cocomazzi, G., Giambra, V., Antinucci, S., Maiorana, A., Giuliani, F., Montomoli, E., Cantaloni, P., Manenti, A., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.847384 · Cited by 15

Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients

Takeshita, M., Nishina, N., Moriyama, S., Takahashi, Y., Ishii, M., Saya, H., Kondo, Y., Kaneko, Y., Suzuki, K., Fukunaga, K., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108999 · Cited by 12

Development and Implementation of Dried Blood Spot-Based COVID-19 Serological Assays for Epidemiologic Studies

Wong, M. P., Meas, M., Adams, C., Hernandez, S., Green, V., Montoya, M., Hirsch, B. M., Horton, M. K., Quach, H., Quach, D. L., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02471-21 · Cited by 15

Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms

Carreño, J. M., Mendu, D. R., Simon, V. R., Shariff, M. A., Singh, G., Menon, V. P., & Krammer, F. (2021) · iScience · doi:10.1016/j.isci.2021.102937 · Cited by 12

Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines

Sepand, M. R., Bigdelou, B., Ho, J. Q., Sharaf, M., Lannigan, A. J., Sullivan, I. M., da Silva, A. P., Barrett, L. O., McGoldrick, S., Lnu, Y., et al. (2022) · Antibodies · doi:10.3390/antib11020035 · Cited by 14

A unique cytotoxic CD4 + T cell‐signature defines critical COVID‐19

Baird, S., Ashley, C. L., Marsh‐Wakefield, F., Alca, S., Ashhurst, T. M., Ferguson, A. L., Lukeman, H., Counoupas, C., Post, J. J., Koneçny, P., et al. (2023) · Clinical & Translational Immunology · doi:10.1002/cti2.1463 · Cited by 12

Blood and saliva SARS-CoV-2 antibody levels in self-collected dried spot samples

Lahdentausta, L., Kivimäki, A. S., Oksanen, L., Tallgren, M., Oksanen, S. A., Sanmark, E., Salminen, A., Geneid, A., Sairanen, M., Paju, S., et al. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00740-x · Cited by 15

Delineating antibody escape from Omicron sublineagesPreprint

Gruell, H., Vanshylla, K., Korenkov, M., Tober‐Lau, P., Zehner, M., Münn, F., Janicki, H., Augustin, M., Schommers, P., Sander, L. E., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.06.487257 · Cited by 13

Recurrent SARS-CoV-2 infections and their potential risk to public health – a systematic review

Abrokwa, S. K., Müller, S. A., Méndez-Brito, A., Hanefeld, J., & Bcheraoui, C. E. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261221 · Cited by 11

Kinetics of neutralizing antibodies against SARS-CoV-2 infection according to sex, age, and disease severity

Kim, Y., Bae, J., Kwon, K. T., Chang, H., Lee, W. K., Park, H., Kim, J., Choi, I., Park, M., & Kim, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-17605-1 · Cited by 12

Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells

Krause, R. G. E., Moyo-Gwete, T., Richardson, S. I., Makhado, Z., Manamela, N. P., Hermanus, T., Mkhize, N. N., Keeton, R., Benede, N., Mennen, M., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00724-9 · Cited by 9

SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise

Duerr, R., Crosse, K. M., Valero-Jimenez, A. M., & Dittmann, M. (2021) · Microorganisms · doi:10.3390/microorganisms9071389 · Cited by 12

Neutralizing antibody responses 300 days after SARS‐CoV‐2 infection and induction of high antibody titers after vaccination

Urlaub, D., Wolfsdorff, N., Hoffmann, J., Dorok, S., Hoffmann, M., Anft, M., Pieris, N., Günther, P. S., Schaaf, B., Cassens, U., et al. (2022) · European Journal of Immunology · doi:10.1002/eji.202149758 · Cited by 11

Longitudinal Analysis of Humoral and Cellular Immune Response up to 6 Months after SARS-CoV-2 BA.5/BF.7/XBB Breakthrough Infection and BA.5/BF.7-XBB Reinfection

Wang, X., Zhang, M., Wei, K., Li, C., Yang, J., Jiang, S., Zhao, C., Zhao, X., Qiao, R., Cui, Y., et al. (2024) · Vaccines · doi:10.3390/vaccines12050464 · Cited by 10

Modelling the concentration of anti-SARS-CoV-2 immunoglobulin G in intravenous immunoglobulin product batches

Stinca, S., Barnes, T. W., Peter, V., Meyers, W., Schulte-Pelkum, J., Filchtinski, D., Steller, L., Hauser, T., Manni, S., Gardiner, D., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259731 · Cited by 10

No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults

Ercanoglu, M. S., Gieselmann, L., Dähling, S., Poopalasingam, N., Detmer, S., Koch, M., Korenkov, M., Halwe, S., Klüver, M., Cristanziano, V. D., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103951 · Cited by 9

Functional Characteristics of Serum Anti-SARS-CoV-2 Antibodies against Delta and Omicron Variants after Vaccination with Sputnik V

Radion, E. I., Mukhin, V. E., Kholodova, A. V., Vladimirov, I. S., Alsaeva, D. Y., Zhdanova, A. S., Ulasova, N. Y., Bulanova, N. V., Makarov, V. V., Keskinov, A. A., et al. (2023) · Viruses · doi:10.3390/v15061349 · Cited by 11

Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19–convalescent individuals

Min, L., Liu, J., Lu, R., Zhang, Y., Du, M., Xing, M., Wu, Z., Kong, X., Zhu, Y., Zhou, X., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.01.005 · Cited by 10

Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility

Lai, A., Caimi, B., Franzetti, M., Bergna, A., Velleca, R., Gatti, A., Rossi, P. L., D'Orso, M. I., Pregliasco, F. E., Balotta, C., et al. (2022) · Vaccines · doi:10.3390/vaccines10030446 · Cited by 10

The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-γ release by natural killer cells

Bilgin, H., Marku, M., Yılmaz, S. S., Yağcı, A., Sili, U., Can, B., Sarınoğlu, R. C., Mülazımoğlu, L., Haklar, G., Şïrïkçï, Ö., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.001 · Cited by 10

Design, Development and Immunogenicity Study of a Multi-Epitope Vaccine Prototype Against SARS-CoV-2

Atanasova, M., Dimitrov, I., Ralchev, N., Markovski, A. M., Manoylov, I. K., Bradyanova, S. L., Mihaylova, N., Tchorbanov, A. I., & Doytchinova, I. A. (2024) · Pharmaceuticals · doi:10.3390/ph17111498 · Cited by 10

Bridging the gap - estimation of 2022/2023 SARS-CoV-2 healthcare burden in Germany based on multidimensional data from a rapid epidemic panel

Harries, M., Jaeger, V. K., Rodiah, I., Hassenstein, M. J., Ortmann, J., Dreier, M., von Holt, I., Brinkmann, M., Dulovic, A., Gornyk, D., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.11.014 · Cited by 9

Knowledge, Attitudes, and Practices of Adult Iraqi Population Towards COVID-19 Booster Dose: A Cross-Sectional Study

Al-Qerem, W. A., Jarab, A. S., Hammad, A. M., Alsajri, A. H., Al-Hishma, S. W., Ling, J., Alabdullah, A. S., Salama, A., & Mosleh, R. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s370124 · Cited by 9

Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity

Henze, L., Braun, J., Meyer‐Arndt, L., Jürchott, K., Schlotz, M., Michel, J., Grossegesse, M., Mangold, M., Dingeldey, M., Kruse, B., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1056525 · Cited by 7

Determination of the frequency of individuals with broadly cross-reactive neutralizing antibodies against PRRSV in the sow population under field conditions

Plaza-Soriano, Á., Martínez-Lobo, F. J., Garza‐Moreno, L., Castillo-Pérez, J., Caballero, E., Castro, J. M., Simarro, I., & Prieto, C. (2024) · Porcine Health Management · doi:10.1186/s40813-024-00372-y · Cited by 8

Humoral immune response and live-virus neutralization of the SARS-CoV-2 omicron (BA.1) variant after COVID-19 mRNA vaccination in children and young adults with chronic kidney disease

Stich, M., Cristanziano, V. D., Tönshoff, B., Weber, L. T., Dötsch, J., Rammer, M. T., Rieger, S., Heger, E., Garbade, S. F., Burgmaier, K., et al. (2022) · Pediatric Nephrology · doi:10.1007/s00467-022-05806-9 · Cited by 8

Risk of waning humoral responses after inactivated or subunit recombinant SARS‐CoV‐2 vaccination in patients with chronic diseases: Findings from a prospective observational study in China

Li, H., Cai, D., Jiang, D., Li, X., Liao, X., Liu, D., Liu, Z., Zhu, P., Yin, G., Ming, J., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28434 · Cited by 7

Identification of berberine as a potential therapeutic strategy for kidney clear cell carcinoma and COVID-19 based on analysis of large-scale datasets

Zheng, Z., Li, X., Nie, K., Wang, X., Liang, W., Yang, F., Zheng, K., & Zheng, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1038651 · Cited by 8

Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients

Dewald, F., Pirkl, M., Paluschinski, M., Kühn, J., Elsner, C., Schulte, B., Knüfer, J., Ahmadov, E., Schlotz, M., Oral, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38127-y · Cited by 9

Evaluation of a Broad Panel of SARS-CoV-2 Serological Tests for Diagnostic Use

Werner, M., Pervan, P., Glück, V., Zeman, F., Koller, M. T., Burkhardt, R., Glück, T., Wenzel, J. J., Schmidt, B., Gessner, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081580 · Cited by 8

Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients

Borgogna, C., Bruna, R., Griffante, G., Martuscelli, L., Andrea, M. D., Ferrante, D., Patriarca, A., Mahmoud, A. M., Gaidano, V., Marchetti, M., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00608-6 · Cited by 8

A prospective study of the impact of glycaemic status on clinical outcomes and anti-SARS-CoV-2 antibody responses among patients with predominantly non-severe COVID-19

Lui, D. T. W., Li, Y. K., Lee, C. H., Chow, W.-S., Lee, A. C. H., Tam, A. R., Pang, P., Ho, T. Y., Cheung, C. Y. Y., Fong, C. H.-Y., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109232 · Cited by 7

Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19

Mellinghoff, S. C., Vanshylla, K., Dahlke, C., Addo, M. M., Cornely, O. A., Klein, F., ten Persigehl, T., Rybniker, J., Gruell, H., & Bröckelmann, P. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.798276 · Cited by 7

Exploring Factors Influencing Changes in Incidence and Severity of Multisystem Inflammatory Syndrome in Children

Castaldo, P., d’Alanno, G., Biserni, G. B., Moratti, M., Conti, F., Fabi, M., & Lanari, M. (2023) · Pathogens · doi:10.3390/pathogens12080997 · Cited by 7

Pseudovirus-Based Neutralization Assays as Customizable and Scalable Tools for Serological Surveillance and Immune Profiling

Denani, C. B., Setatino, B. P., Pereira, D., Horbach, I. S., Azevedo, A. D. S., Coutinho, G., Ferroco, C. L. D. V., Xavier, J. R., Leite, R., dos Santos, E. A. P., et al. (2025) · Pathogens · doi:10.3390/pathogens14111129 · Cited by 7

Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19

Thibeault, C., Bardtke, L., Vanshylla, K., Cristanziano, V. D., Eberhardt, K. A., Stubbemann, P., Hillus, D., Tober‐Lau, P., Mukherjee, P., Münn, F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.166711 · Cited by 6

Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study

Griffante, G., Chandel, S., Ferrante, D., Caneparo, V., Capello, D., Bettio, V., Borgogna, C., Aleni, C., Esposito, S., Sarro, A., et al. (2021) · Viruses · doi:10.3390/v13112270 · Cited by 6

The comprehensive insights into the B-cells-mediated immune response against COVID-19 infection amid the ongoing evolution of SARS-CoV-2

Dhawan, M. K., Thakur, N., Sharma, M. K., & Rabaan, A. A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117936 · Cited by 5

Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment

Carlin, A. F., Clark, A. E., Garretson, A. F., Bray, W. A., Porrachia, M., Santos, A. T., Rana, T. M., Chaillon, A., & Smith, D. M. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad154 · Cited by 5

Probabilistic classification of anti‐SARS‐CoV‐2 antibody responses improves seroprevalence estimates

Dopico, X. C., Muschiol, S., Grinberg, N. F., Aleman, S., Sheward, D. J., Hanke, L., Ahl, M., Vikström, L., Forsell, M. N. E., Coquet, J. M., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1379 · Cited by 4

Infection in asymptomatic carriers of SARS-CoV-2 can interfere with the achievement of robust immunity on a population scale

Viana, K. F., Zarpelon, L. F. B., Leandro, A., Terêncio, M. L., Lopes, R. D., Martins, C. A., Silva, I., Sibim, A. C., Marques, F., SILVA, R. D., et al. (2021) · Journal of General Virology · doi:10.1099/jgv.0.001684 · Cited by 4

Long-Term Cross Immune Response in Mice following Heterologous Prime-Boost COVID-19 Vaccination with Full-Length Spike mRNA and Recombinant S1 Protein

Li, D., Zhao, H., Liao, Y., Jiang, G., Cui, P., Zhang, Y., Yu, L., Fan, S., Li, H., & Li, Q. (2023) · Vaccines · doi:10.3390/vaccines11050963 · Cited by 4

Population-based study of the durability of humoral immunity after SARS-CoV-2 infection

Peterhoff, D., Wiegrebe, S., Einhauser, S., Patt, A. J., Beileke, S., Günther, F., Steininger, P. A., Niller, H. H., Burkhardt, R., Küchenhoff, H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1242536 · Cited by 4

Hybrid Immunity from Gam-COVID-Vac Vaccination and Natural SARS-CoV-2 Infection Confers Broader Neutralizing Activity against Omicron Lineage VOCs Than Revaccination or Reinfection

Викторович, К. С., Guselnikov, S. V., Nekrasov, B. G., Molodykh, S. V., Kuvshinova, I. N., Murasheva, S. V., Николаевна, Б. Т., Gorchakov, A. A., Chikaev, A. N., Chikaev, N. A., et al. (2024) · Vaccines · doi:10.3390/vaccines12010055 · Cited by 4

Age- and sex-based changes in spike protein antibody status after SARS-CoV-2 vaccination and effect of past-infection in healthcare workers in Osaka

Hoshida, S., Koeda, N., Hattori, H., Tanaka, M., Tanaka, I., Fukui, H., Fujita, J., Sasaki, Y., & Tamura, S. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07695-7 · Cited by 5

Kinetics and Correlates of the Neutralizing Antibody Response to SARS-CoV-2Preprint

Vanshylla, K., Cristanziano, V. D., Kleipass, F., Dewald, F., Schommers, P., Gieselmann, L., Gruell, H., Schlotz, M., Ercanoglu, M. S., Stumpf, R., et al. (2021) · SSRN Electronic Journal · doi:10.1101/2021.01.26.428207 · Cited by 7

Stable neutralizing-antibody levels 6 months after mild and severe COVID-19 episode

Pradenas, E., Trinité, B., Urrea, V., Marfil, S., Ávila‐Nieto, C., de la Concepción, M. L. R., Tarrés-Freixas, F., Izquierdo‐Useros, N., Paredes, R., Mateu, L., et al. (2021) · Topics in antiviral medicine · Cited by 1

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike

Prévost, J., Gasser, R., Beaudoin-Bussières, G., Richard, J., Duerr, R., Laumaea, A., Anand, S. P., Goyette, G., Benlarbi, M., Ding, S., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100126 · Cited by 203

Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patientsPreprint

Chansaenroj, J., Yorsaeng, R., Wanlapakorn, N., Chirathaworn, C., Sudhinaraset, N., Sripram, M., Chalongviriyalert, P., Jirajariyavej, S., Kiatpanabhikul, P., Saiyarin, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1073046/v1 · Cited by 3

Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes

Pradenas, E., Trinité, B., Urrea, V., Marfil, S., Ávila‐Nieto, C., de la Concepción, M. L. R., Tarrés-Freixas, F., Pérez-Yanes, S., Rovirosa, C., Ainsua‐Enrich, E., et al. (2021) · Med · doi:10.1016/j.medj.2021.01.005 · Cited by 106